The International Conference on Cancer Science and Research (Hybrid Event) will be held from November 17-19, 2025, in Singapore and Online. This premier global event is dedicated to advancing knowledge and collaboration in the field of Oncology. Cancer 2025 will bring together leading researchers, oncologists, healthcare professionals, and industry experts from across the globe to discuss the latest breakthroughs in cancer research and treatment. The conference will feature a comprehensive program, including keynote presentations from renowned experts, interactive oral and poster sessions, and dynamic panel discussions. Key topics will encompass a wide range of areas in cancer science, such as molecular biology, cancer immunotherapy, early detection and diagnostics, and prevention strategies. Attendees will have ample opportunities to connect with peers, exchange ideas, and establish professional relationships through networking events, and informal gatherings, fostering collaboration and innovation essential for tackling the challenges in cancer research and treatment.
Networking is a key component of the conference, offering participants the chance to connect with fellow professionals and establish collaborative relationships that can lead to impactful research partnerships. Join us to be part of a transformative event that aims to advance cancer research, improve patient care, and ultimately contribute to a world free of cancer. Your participation will play a crucial role in shaping the future of oncology and fostering collaboration among the global cancer community. Together, we can make significant strides in understanding and combating cancer.
University of California San Francisco School of Medicine, United States
Institute of Radiological Protection and Nuclear Safety, France
The Mathews Journal of Cancer Science is proud to serve as the supporting journal for this upcoming event on Cancer Science and Research. As part of this collaboration, a DOI will be assigned to the conference proceedings book, ensuring the research and findings presented at the event are globally accessible and citable. Additionally, participants who wish to publish their full-length research articles have the opportunity to submit their manuscripts for consideration in the Mathews Journal of Cancer Science. This is an excellent platform for researchers and professionals to share their contributions to the field, receive peer-reviewed recognition, and enhance the visibility of their work. Article processing charges are completely f...
We are thrilled to partner with the peer-reviewed journal Psycho-Oncologie to publish a dedicated special issue featuring the best work presented at the International Conference on Cancer Science and Research 2025. All confirmed participants can convert their conference presentations into full manuscripts and enjoy an exclusive discount on the journal’s article-processing charge. Submissions will be fast-tracked through peer review and accepted articles will appear online on a rolling basis—maximizing visibility in major indexing databases.
Psycho-oncologie (PO, eISSN: 1778-381X) is a leading international journal dedicated to exploring the psychosocial, behavioral, and ethical aspects of cancer. It brings together research from psychology...
Comprehensive market insights, trends, and projections driving the future of oncology research and treatment innovation
Projected to reach $866.1B by 2034
10.8% CAGR
Expected to rise to $409B by 2028
12.5% CAGR
From $26.6B to $154.6B by 2030
Explosive growth expected
The worldwide oncology market generated USD 320.3 billion in 2024 and is forecast to reach USD 866.1 billion by 2034 (10.8% CAGR). These drivers will be unpacked during our flagship cancer conference series.
Global spending on cancer medicines hit USD 223 billion in 2023 and is projected to rise to USD 409 billion by 2028, a trend analysed in finance workshops at our upcoming cancer conferences.
Revenues expected to climb from USD 26.6 billion (2021) to USD 154.6 billion (2030) (22.9% CAGR). Our next international cancer conference spotlights novel bispecifics and checkpoint combinations.
Multi-omic profiling is fuelling adaptive trials—a plenary focus at Cancer Conference Singapore.
Foundational AI models now exceed 94% accuracy across 11 tumour types—debated on panels at global cancer conferences.
FDA-cleared blood tests such as Shield signal mainstream adoption; implementation pathways feature in pre-conference workshops.
Comprehensive market projections and key performance indicators driving the oncology sector forward.
| Indicator | 2024/25 Baseline | 2030 | 2034/35 | CAGR |
|---|---|---|---|---|
| Global oncology market size | USD 356 B (2025) | – | USD 866 B (2034) | 10.8% |
| Immuno-oncology market | USD 26.6 B (2021) | USD 154.6 B | – | 22.9% |
| Cancer medicine spend | USD 223 B (2023) | USD 409 B (2028) | – | 12.5% |
| Annual new cancer cases | 20 M (2022) | – | 35 M (2050) | – |
Seven FDA-approved CAR-T products are on the market, with solid-tumour candidates showing early efficacy—featured in our "Frontiers in Cell Therapy" cancer conference symposium.
Phase III read-outs for melanoma and pancreatic candidates expected by 2026, opening a USD 15 billion sub-segment—watch live updates during poster sessions.
Actinium-225-labelled PSMA ligands advance into pivotal studies; insights covered in the "Radionuclide Therapy" track.
AstraZeneca has earmarked USD 3.5 billion for new oncology R&D and manufacturing (2024-2026)—a keynote case at the Global Cancer Conference & Expo.
Oncology captured >36% of global life-science VC dollars in 2024, led by AI drug-design start-ups—network with investors in dedicated cancer conference pitch sessions.
Asia-Pacific is the fastest-growing buyer of immuno-oncology, driven by reform-led access expansion—a focus forum at our Singapore cancer conference.
Without decisive prevention, the world faces 35 million new cancer cases each year by 2050—a central policy debate in our plenary cancer conference sessions.
Partner early in AI-diagnostic validation—meet potential collaborators at our international cancer conference.
Prioritise combination trials—shared clinical case studies during combination-therapy sessions.
Leverage emerging markets—regulatory masterclass at the Singapore cancer conference.
Close access gaps—join round-tables on affordability and real-world evidence.
Gardens by the Bay
Marina Bay Sands
Merlion Park
Sentosa Island
Copyright 2024 Mathews International LLC All Rights Reserved
